AlzeCure Pharma AB (FRA:AC6) Total Liabilities: €2.75 Mil (As of Mar. 2026)


FRA:AC6 AlzeCure Pharma AB FRA:AC6
33 GF Score
Price €0.53
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB Total Liabilities?

AlzeCure Pharma AB FRA:AC6 -6.97% 33 Total Liabilities is €2.75 Mil as of Mar. 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

AlzeCure Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was €2.75 Mil.

AlzeCure Pharma AB's quarterly Total Liabilities increased from Sep. 2025 (€1.45 Mil) to Dec. 2025 (€2.40 Mil) and increased from Dec. 2025 (€2.40 Mil) to Mar. 2026 (€2.75 Mil).

AlzeCure Pharma AB's annual Total Liabilities declined from Dec. 2023 (€1.26 Mil) to Dec. 2024 (€1.15 Mil) but then increased from Dec. 2024 (€1.15 Mil) to Dec. 2025 (€2.40 Mil).

AlzeCure Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB Total Liabilities Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 1.23 0.94 1.26 1.15 2.40

AlzeCure Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.91 1.45 2.40 2.75
FRA:AC6
33GF Score
AlzeCure Pharma AB FRA:AC6
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AlzeCure Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.165+(0.235+-1.1102230246252E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.40

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=5.426-3.025
=2.40

AlzeCure Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.533+(0.213+8.3266726846887E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.75

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=3.788-1.042
=2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €2.75 Mil mean?
AlzeCure Pharma AB (FRA:AC6) has a Total Liabilities of €2.75 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AlzeCure Pharma AB and its competitors.
Is AlzeCure Pharma AB's Total Liabilities too high?
AlzeCure Pharma AB's current Total Liabilities is €2.75 Mil. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's Total Liabilities compare to VRTX and REGN?
AlzeCure Pharma AB's Total Liabilities of €2.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current Total Liabilities is €2.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current Total Liabilities of €2.75 Mil. The current Total Liabilities is €2.75 Mil. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current Total Liabilities is €2.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score

Get the complete analysis for FRA:AC6

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price